---
title: <em>PD-L1</em> (<em>CD274</em>) promoter hypomethylation predicts immunotherapy
  response in metastatic urothelial carcinoma
date: '2023-10-23'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37868689/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231023180908&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: PD-L1 status assessed by immunohistochemistry (IHC) has failed to reliably
  predict outcomes for patients with metastatic urothelial carcinoma (mUC) on immune
  checkpoint blockade (ICB). PD-L1 promoter methylation is an epigenetic mechanism
  that has been shown to regulate PD-L1 mRNA expression in various malignancies. The
  aim of our present study was to evaluate the predictive potential of PD-L1 promoter
  methylation status (mPD-L1) in ICB-treated mUC compared to conventional IHC-based
  ...
disable_comments: true
---
PD-L1 status assessed by immunohistochemistry (IHC) has failed to reliably predict outcomes for patients with metastatic urothelial carcinoma (mUC) on immune checkpoint blockade (ICB). PD-L1 promoter methylation is an epigenetic mechanism that has been shown to regulate PD-L1 mRNA expression in various malignancies. The aim of our present study was to evaluate the predictive potential of PD-L1 promoter methylation status (mPD-L1) in ICB-treated mUC compared to conventional IHC-based ...